Lactobacillus casei CCFM1059 stands out from traditional strains in providing targeted anti-inflammatory and immune benefits primarily due to its national invention patent. It helps specifically upregulate the expression of IL-22 in the gut, which helps support gut health and maintain the intestinal immune barrier. Additionally, this strain utilizes advanced 5-layer microencapsulation technology. This technology helps overcome the common challenge of probiotic inactivation in the gastrointestinal tract, helping to ensure that active immune-modulating factors are delivered effectively to the intestines to support targeted interventions.
This targeted anti-inflammatory capability is rooted in its unique immune-modulating mechanism. Scientific research indicates that CCFM1059 helps specifically increase the secretion of interleukins, particularly IL-22. IL-22 plays a key role in supporting the integrity of the intestinal mucosal barrier and promoting tissue repair. By helping to upregulate the expression of this key immune factor, CCFM1059 helps modulate excessive inflammatory responses in the gut, providing precise immune support for individuals with sensitive digestive systems. This specific targeting mechanism differentiates it from many traditional probiotics.
Furthermore, its advanced technological framework provides a solid foundation for its efficacy. The 5-layer microencapsulation technology acts as a protective shield for the probiotic. This technology not only helps enhance the strain's tolerance to gastric acid and bile salts but also helps ensure its stable survival and colonization in the complex intestinal microenvironment. When the highly active strain reaches the intestines, its patented IL-22 upregulating potential can be fully realized, providing brand owners with a highly competitive formulation advantage for developing next-generation, high-value anti-inflammatory and immune supplements.